| ABOUT BAYBIOGET INVOLVEDEVENT CENTER
MEMBER CENTERINFORMATION CENTERMEDIA CENTERCAREER CENTER |
Developing Treatments for Ovarian Cancer Sponsored by:
![]() With Support From: ![]() Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States. Although incidence rates have been declining since the early 1990s, the five-year survival rate has increased by a mere 8 percent over the past 30 years. According to the Ovarian Cancer National Alliance, while one in 72 women will develop ovarian cancer in their lifetime, one in 95 will die as a result of the disease. If diagnosed and treated early, however, ovarian cancer can often be cured. With the potential to have a significant impact on the treatment of ovarian cancer, many companies in Northern California’s life sciences industry are focusing product development efforts on the disease. Please join us to learn more about their approach and their hope for future treatments for ovarian cancer. Panel Moderator:Emily Hua Vice President, Brand Management Practice, Campbell Alliance Panel Speakers: Stephen M. Kelsey, MD FRCP FRCPath Vice President, Clinical Hematology/Oncology, Genentech Inc Robert Levack Senior Product Manager Oncology Pipeline, Genentech Lesley Stolz, PhD Vice President, Corporate and Business Development, Sunesis Pharmaceuticals
Registrations: If you are an employee of a Partner or Sponsor company, please contact Program Director, Misha Tsirulnikov to obtain your complimentary registration. On-line reservations: CLICK HERE Reservations by mail or fax: CLICK HERE
Is your company a member? Click here to check. See how your company can save money by becoming a BayBio member! |